Miniaturized flow cytometry-based BCR-ABL immunoassay in detecting leptomeningeal disease

F. D'Alessio, P. Mirabelli, E. Mariotti, M. Raia, R. di Noto, G. Fortunato, A. Camera, L. del Vecchio

Research output: Contribution to journalArticlepeer-review


Despite central nervous system (CNS) prophylactic programs limit leptomeningeal involvement in acute lymphoblastic leukemia (ALL), it can still occur in a restricted percentage of cases. The exact risk rate remains still unknown, and several factors are associated with an increased probability to develop CNS involvement. Among them, Philadelphia (Ph)-positive genotype seems to play a relevant role. Recently, a flow cytometric assay to detect BCR-ABL protein has been developed, but little is known about its possible employment in leptomeningeal disease. Here, we show the miniaturized application of the original assay for BCR-ABL oncoprotein detection in cerebrospinal fluid (CSF) samples.

Original languageEnglish
Pages (from-to)1290-1293
Number of pages4
JournalLeukemia Research
Issue number10
Publication statusPublished - Oct 2011


  • BCR-ABL oncoprotein
  • Cerebrospinal fluid
  • Flow cytometry
  • Immunobead assay
  • Philadelphia-positive leukemia

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology


Dive into the research topics of 'Miniaturized flow cytometry-based BCR-ABL immunoassay in detecting leptomeningeal disease'. Together they form a unique fingerprint.

Cite this